DeepQure Confirms 51 mmHg Average Blood Pressure Reduction in Korean Clinical Study

Medical device developer DeepQure announced that its next-generation hypertension treatment device HyperQure™ is nearing completion of its Korean clinical study, while U.S. clinical collaborations with major hospitals are accelerating.

In the Korean study, nine participants saw their average blood pressure decrease from 165 mmHg pre-procedure to 114 mmHg at 12 months, confirming an average reduction of 51 mmHg. According to the company, this outcome is more than ten times greater than results reported with FDA-approved catheter-based (intravascular) renal denervation (RDN) systems, and is viewed as evidence supporting both the effectiveness and safety of laparoscopic, extravascular RDN.

Building on domestic results, DeepQure is expediting entry into the U.S. market. A multi-center IDE clinical trial is underway at five leading institutions: Stanford University, Mayo Clinic, University of California, Irvine, University of Florida, and Henry Ford Hospital.

Clinical execution in the U.S. has been further strengthened by the addition of Jason Jones, who previously led clinical programs at global RDN developer SoniVie. In March, SoniVie was acquired by Boston Scientific for $540 million.

RDN is recognized as an innovative therapeutic option for patients with resistant hypertension who do not achieve control with medication. Industry interest has been rising: in 2010, Medtronic acquired Ardian, the first developer of an RDN device, in a deal valued at $800 million, underscoring the field’s growth potential. Market research firm iHealthcareAnalyst projects the global RDN device market will reach $15.5 billion by 2033.

DeepQure says its laparoscopic, extravascular approach is designed to deliver both safety and therapeutic benefit relative to existing products, differentiating the company from global competitors. The company notes strong interest from multiple major medtech firms and is in discussions on strategic collaboration with one global player.

A DeepQure spokesperson commented: “HyperQure™ is an innovative technology that enables a more fundamental treatment approach for hypertension. On the back of results demonstrated in our Korean clinical study, we are accelerating our expansion into the U.S. and global markets. Our goal is to set a new paradigm in hypertension treatment with technology developed in Korea.”

Source